Abbott ARCHITECT Clinical Chemistry and Immunoassay Systems: Digoxin Assays Are Free of Interferences From Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone

作者：DeFrance Andrea; Armbruster David; Petty Diana; Cooper Kelley C; Dasgupta Amitava^*

来源：Therapeutic Drug Monitoring, 2011, 33(1): 128-131.

DOI：10.1097/FTD.0b013e3181fd4c30

• spironolactone
• canrenone
• potassium canrenoate
• ARCHITECT digoxin

Spironolactone, which is metabolized to canrenone, is often used in combination with digoxin. Potassium canrenoate is a similar drug that is also metabolized to canrenone. As a result of reported interference of spironolactone, potassium canrenoate, and their common metabolite canrenone with digoxin immunoassays, we investigated potential interference of these compounds with two relatively new digoxin assays for application on ARCHITECT clinical chemistry platforms (cDig, particle-enhanced turbidimetric inhibition immunoassay) and ARCHITECT immunoassay platforms (iDig, chemiluminescent microparticle immunoassay), both from Abbott Diagnostics. When aliquots of drug-free serum pool were supplemented with various amounts of spironolactone, potassium canrenoate, and canrenone, no apparent digoxin concentration was observed using cDig assay on ARCHITECT c4000, c8000, and c16000 or iDig assay on i1000SR and i2000SR analyzers. In addition, we observed no false increase in serum digoxin value when aliquots of a digoxin pool were further supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone. We conclude that both the cDig and iDig assays on the ARCHITECT analyzers are free from interferences by spironolactone, potassium canrenoate, and canrenone.

• 出版日期2011-2